NextCure  Inc

NASDAQ NXTC

Data sourced from iex and EODHD
Download Data

NextCure  Inc Liabilities to Equity Ratio 3 year CAGR for the quarter ending March 31, 2024: 56.70%

NextCure  Inc Liabilities to Equity Ratio 3 year CAGR is 56.70% for the quarter ending March 31, 2024, a 59.11% change year over year. The liabilities to equity ratio, also known as the leverage ratio, measures the proportion of a company's total liabilities to its shareholders' equity. It is calculated by dividing the total liabilities by the shareholders' equity. This ratio provides insights into the extent to which a company relies on debt financing compared to equity financing. A higher ratio indicates higher financial leverage, which can amplify both returns and risks for the company's shareholders. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • NextCure  Inc Liabilities to Equity Ratio for the quarter ending March 31, 2023 was 0.09, a 113.98% change year over year.
  • NextCure  Inc Liabilities to Equity Ratio for the quarter ending March 31, 2022 was 0.04, a -2.58% change year over year.
  • NextCure  Inc Liabilities to Equity Ratio for the quarter ending March 31, 2021 was 0.04, a 19.70% change year over year.
  • NextCure  Inc Liabilities to Equity Ratio for the quarter ending March 31, 2020 was 0.04, a 100.94% change year over year.
NASDAQ: NXTC

NextCure  Inc

CEO Mr. Michael S. Richman MSBA
IPO Date May 9, 2019
Location United States
Headquarters 9000 Virginia Manor Road, Beltsville, MD, United States, 20705
Employees 82
Sector Healthcare
Industry Biotechnology
Description

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

StockViz Staff

September 20, 2024

Any question? Send us an email